Digital Health Startup Leverages IT with Eyes on Reversing Type 2 Diabetes | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Digital Health Startup Leverages IT with Eyes on Reversing Type 2 Diabetes

March 13, 2017
by Rajiv Leventhal
| Reprints

San Francisco-based digital health startup Virta Health is leveraging artificial intelligence (AI) and personalized care treatment plans to reverse type 2 diabetes, the company stated last week in an announcement.

Virta Health is a new company founded by a team of physicians, scientists, and technologists trained at Stanford, MIT, and Harvard. The company’s debut comes on the heels of a new peer-reviewed study in JMIR Diabetes that demonstrates Virta was successful in reversing type 2 diabetes in half of its clinical trial patients and eliminating or reducing insulin in 87 percent of patients in just 10 weeks.

Specifically, Virta Health is an online specialty medical clinic that has the goal to reverse type 2 diabetes safely and sustainably, without medications or surgery—shifting the focus from diabetes management to reversal. Virta helps lower hemoglobin A1C while reducing or eliminating medications in an online setting with continuous, remote care delivered by a dedicated physician and health coach.

“Until now, the only clinically proven way to reverse diabetes was bariatric surgery. For the first time, people with type 2 diabetes have an alternative to surgery, which is risky, costly and not covered for most people, and also to ongoing management with medications like insulin,” Sami Inkinen, co-founder and CEO of Virta Health, said in a statement. “Our mission is to reverse diabetes in 100 million people by 2025. It’s an ambitious goal, but we’re motivated every day by the lives we’ve already changed.”

Virta is backed by $37 million in funding from some major investors, including: Venrock, Allen & Company, Ev William’s Obvious Ventures, Redmile Group, and PayPal and Affirm founder Max Levchin’s Scifi VC.

Drawing on decades of research, including that of its founders and advisors, Virta is driving two major innovations. First, officials attest that Virta’s science takes a highly individualized approach to carbohydrate intake and nutritional ketosis (when a body burns fat as its primary fuel source instead of glucose). And second, Virta’s technology platform and artificial intelligence enable continuous, remote care and ongoing personalization of each patient’s care plan, delivered online by Virta physicians and health coaches.

Taken together, these innovations enable Virta to deliver the type of high-engagement, personalized care required to reverse type 2 diabetes safely and sustainably at scale. The clinic does this by providing physician supervision, a dedicated health coach, app and biomarker tracking tools, a community of peers, and a personalized nutrition and care plan, officials note.

“Virta has shown that diabetes can be controlled in many patients without the need for medication or surgery. If we can get this treatment to more and more Americans, we can have a huge impact on their lives and reduce one of the most significant drivers of healthcare cost growth,” said Robert Ratner, M.D., former chief scientific and medical officer of the American Diabetes Association.

Results published in the above-mentioned study from a Virta clinical trial run in partnership with Indiana University Health Arnett  showed that within 10 weeks, 56 percent of patients lowered their blood glucose to a non-diabetic range (as measured by A1c below 6.5 percent), and 87 percent reduced or completely eliminated insulin. Moreover, Virta patients experienced 7.2 percent weight loss on average, with 71 percent of participants achieving the clinically significant threshold of 5 percent. More than 90 percent of initial patients completed their individualized care plan.

“These early results indicate that when delivered with continuous online support, a highly individualized care plan focused on carbohydrate intake and nutritional ketosis can be very effective in improving glycemic control and weight loss in adults with type 2 diabetes while decreasing or eliminating diabetes medication use,” said Sarah Hallberg, medical director at Virta Health, and report co-author.

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

Study will Leverage Connecticut HIE to Help Prevent Suicides

A new study will aim to leverage CTHealthLink, a physician-led health information exchange (HIE) in Connecticut, to help identify the factors leading to suicide and to ultimately help prevent those deaths.

Duke Health First to Achieve HIMSS Stage 7 Rating in Analytics

North Carolina-based Duke Health has become the first U.S. healthcare institution to be awarded the highest honor for analytic capabilities by HIMSS Analytics.

NIH Releases First Dataset from Adolescent Brain Development Study

The National Institutes of Health (NIH) announced the release of the first dataset from the Adolescent Brain Cognitive Development (ABCD) study, which will enable scientists to conduct research on the many factors that influence brain, cognitive, social, and emotional development.

Boston Children's Accelerates Data-Driven Approach to Clinical Research

In an effort to bring a more data-driven approach to clinical research, Boston Children’s Hospital has joined the TriNetX global health research network.

Paper Records, Films Most Common Type of Healthcare Data Breach, Study Finds

Despite the high level of hospital adoption of electronic health records and federal incentives to do so, paper and films were the most frequent location of breached data in hospitals, according to a recent study.

AHA Appoints Senior Advisor for Cybersecurity and Risk

The American Hospital Association (AHA) has announced that John Riggi has joined the association as senior advisor for cybersecurity and risk.